Gestational Diabetes Market Research Report – Forecast till 2027

Gestational Diabetes Market Research Report, By Type (Type A1, Type A2), Administration (Oral, Intravenous), Treatment (Monitoring, Drug Treatment, Non-Pharmacological Treatment), End User (Hospital, Retail Pharmacy) - Forecast till 2027

ID: MRFR/Pharma/3172-HCR | February 2021 | Region: Global | 90 pages

Gestational Diabetes Market Scenario:


Diabetes is a metabolic disorder in which the body glucose level is elevated. Gestational diabetes is a temporary or permanent form of diabetes in which the body daoes not produce adequate amounts of insulin to regulate sugar during pregnancy. It may also be called glucose intolerance or carbohydrate intolerance. According to the International Diabetes Federation in 2016, it was estimated that 420 million adult population is suffering from diabetes which is increasing at the rate of 8.4% and is expected to reach 625 million by 2040. According to the American Pregnancy Association, approximately 2-5% of pregnant women develop gestational diabetes; this number may increase to 7-9% of mothers who are more likely to have risk factors. Increasing prevalence of the gestational diabetic population is the major driving factor for the growth of the gestational diabetes market. Moreover, increasing obese population, increasing healthcare expenditure, and strong encouragement from the government have also contributed to the growth of the gestational diabetes market. According to research, smoking increases the possibility of diabetes; more than 60% of the global population smokes, this has increased the risk of diabetes and contributed to the growth of the gestational diabetes market. However, lack of awareness among people and cost issues may lead to restrain the growth of the market.


The gestational diabetes market is expected to grow at a CAGR of 5.4% during forecast period. 


Intended Audience



  • Biotechnological institutes

  • Pharmaceutical companies

  • Government and Private Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Medical Research Laboratories 


Figure 1:- Global gestational diabetes market share, by region Global gestational diabetes market

    Annual reports, Press release, White paper, Company Presentation
Segmentation


The gestational diabetes market is segmented on the basis of types, administration, treatment, and end users.


On the basis of types, the gestational diabetes market is segmented into type A1, type A2 and others.


On the basis of administration, the gestational diabetes market is categorised into oral, intravenous, and other.


On the basis of treatment, the gestational diabetes market is segmented into monitoring, drug treatment, and non-pharmacological treatment. Monitoring is further segmented into urinary glucose testing, oral glucose tolerance test, and others. Drug treatment is subsegmented into insulin, sensitizers, SGLT-2 inhibitors, alpha-glucosidase inhibitors, and others


On the basis of end users, the gestational diabetes market is segmented into hospital, retail pharmacy and other.


Regional Analysis


America dominates the gestational diabetes market owing to large patient population. Apart from this, increasing number of obese people, changing lifestyle and increasing healthcare expenditure have boosted the growth of the market in America. According to the Centers for Disease Control and Prevention (2014), 73.5 million adults in the US were diagnosed with high cholesterol level. Increasing cholesterol level and smoking increases the possibility of causing diabetes. Additionally, increasing awareness among the people regarding different monitoring procedures and well-developed technology has also contributed to the growth of the market.


Europe is the second largest gestational diabetes market, which is followed by Asia Pacific. Huge smoking population, availability of funds for research, and government support for research & development will drive the market.


Asia Pacific is the fastest growing region for the market due to the presence of a huge patient population, continuously developing economies, and increasing need for the better treatment.


On the other hand, the Middle East & Africa has the least share in the gestational diabetes market due to presence of poor economy especially in Africa region. Majority of the market of this region is hold by Middle East due to well-developed healthcare sector and huge healthcare expenditure.


 


Research Methodology
gestational diabetes market


Sources: WHO, annual reports, press release, white paper, and company presentation 


Key players for gestational diabetes market


Antares Pharma (US), INJEX Pharma AG (Germany), 3M (US), Eli Lilly (US), Biocon (US), Sunpharma (India), Sanofi (France), Novo Nordisk (Denmark), Abbott (US), AstraZeneca (UK), Novartis (Switzerland), Daiichi Sankyo (Japan), Boehringer Ingelheim (Germany), Merck & Co. (US), Pfizer (US), Akros Pharma (US), Amgen (US), Adocia (France), Peptron (South Korea), and Takeda (Japan).



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   5.4% (2017-2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Types, Administration, Treatment, and End Users
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Antares Pharma (US), INJEX Pharma AG (Germany), 3M (US), Eli Lilly (US), Biocon (US), Sunpharma (India), Sanofi (France), Novo Nordisk (Denmark), Abbott (US), AstraZeneca (UK), Novartis (Switzerland), Daiichi Sankyo (Japan), Boehringer Ingelheim (Germany), Merck & Co. (US), Pfizer (US), Akros Pharma (US), Amgen (US), Adocia (France), Peptron (South Korea), and Takeda (Japan).
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • Increasing prevalence of the gestational diabetic population
  • Increasing obese population
  • Increasing healthcare expenditure
  • Strong encouragement from the government


  • Speak to Analyst Ask for Customization

    TABLE OF CONTENT

    Chapter 1. Report Prologue

    Chapter 2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    Chapter 3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary research

    3.4 Market Size Estimation

    Chapter 4. Market Dynamics

    4.1 Drivers

    4.2 Restrains

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Technology Trends & Assessment

    Chapter 5. Market Factor Analysis

    5.1 Porters Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    Chapter 6. Global Gestational Diabetes Market, by Type

    6.1 Introduction

    6.2 Type A1

    Market Estimates & Forecast, 2020 – 2027

    6.3 Type A2

    Market Estimates & Forecast, 2020 – 2027

    6.4 Others

    Market Estimates & Forecast, 2020 – 2027

    Chapter 7. Global Gestational Diabetes Market, by Administration

    7.1 Introduction

    7.2 Oral

    Market Estimates & Forecast, 2020 – 2027

    7.3 Intravenous

    Market Estimates & Forecast, 2020 – 2027

    7.4 Others

    Market Estimates & Forecast, 2020 – 2027

    Chapter 8. Global Gestational Diabetes Market, by Treatment

    8.1 Introduction

    8.2 Monitoring

    Market Estimates & Forecast, 2020 – 2027

    8.2.1 Urinary Glucose Testing

    8.2.2 Oral Glucose Tolerance Test

    8.2.3 Others

    8.3 Drug Treatment

    Market Estimates & Forecast, 2020 – 2027

    8.3.1 Insulin

    8.3.2 Sensitizers

    8.3.3 SGLT-2 Inhibitors

    8.3.4 Alpha-Glucosidase Inhibitors

    8.3.5 Others

    8.4 Non-Pharmacological Treatment

    Market Estimates & Forecast, 2020 – 2027

    Chapter 9 Global Gestational Diabetes Market, by End User

    9.1 Introduction

    9.2 Hospitals

    9.2.1 Market Estimates & Forecast, 2020 – 2027

    9.3 Retail Pharmacy

    9.2.2 Market Estimates & Forecast, 2020 – 2027

    9.4 Others

    Chapter 10. Global Gestational Diabetes Market, by Region

    10.1 Introduction

    10.2 America

    10.2.1 North America

    10.2.1.1 US

    10.2.1.1 Canada

    10.2.2 South America

    10.3 Europe

    10.3.1 Western Europe

    10.3.1.1 Germany

    10.3.1.2 France

    10.3.1.3 Italy

    10.3.1.4 Spain

    10.3.1.5 UK

    10.3.1.6 Rest of Western Europe

    10.3.2 Eastern Europe

    10.4 Asia Pacific

    10.4.1 Japan

    10.4.2 China

    10.4.3 India

    10.4.4 Australia

    10.4.5 Republic of Korea

    10.4.6 Rest of Asia Pacific

    10.5 The Middle East & Africa

    10.5.1 United Arab Emirates

    10.5.2 Saudi Arabia

    10.5.3 Oman

    10.5.4 Kuwait

    10.5.5 Qatar

    10.5.6 Rest of the Middle East & Africa

    Chapter 11 Company Landscape

    11.1 Introduction

    11.2 Market Share Analysis

    11.3 Key Development & Strategies

    11.3.1 Key Developments

    Chapter 12 Company Profiles

    12.1 Novartis AG

    12.1.1 Company Overview

    12.1.2 Product Overview

    12.1.3 Financials

    12.1.4 SWOT Analysis

    12.2 Antares Pharma

    12.2.1 Company Overview

    12.2.2 Product Overview

    12.2.3 Financial Overview

    12.2.4 Key Developments

    12.2.5 SWOT Analysis

    12.3 Eli Lilly

    12.3.1 Company Overview

    12.3.2 Product Overview

    12.3.3 Financial Overview

    12.3.4 Key Development

    12.3.5 SWOT Analysis

    12.4 Biocon

    12.4.1 Company Overview

    12.4.2 Product/Business Segment Overview

    12.4.3 Financial Overview

    12.4.4 Key Development

    12.4.5 SWOT Analysis

    12.5 Sanofi

    12.5.1 Company Overview

    12.5.2 Product Overview

    12.5.3 Financial overview

    12.5.4 Key Developments

    12.6 Abbott

    12.6.1 Company Overview

    12.6.2 Product Overview

    12.6.3 Financial Overview

    12.6.4 Key Developments

    12.7 AstraZeneca

    12.7.1 Overview

    12.7.2 Product Overview

    12.7.3 Financials

    12.7.4 Key Developments

    12.7.5 SWOT Analysis

    12.8 Others

    Chapter 13 MRFR Conclusion

    13.1 Key Findings

    13.1.1 From CEO’s View Point

    13.1.2 Unmet Needs of the Market

    13.2 Key Companies to Watch

    13.3 Prediction of Pharmaceutical industry

    Chapter 14 Appendix

    LIST OF TABLES

    Table 1 Gestational Diabetes Industry Synopsis, 2020 – 2027

    Table 2 Global Gestational Diabetes Market Estimates and Forecast, 2020 – 2027, (USD Million)

    Table 3 Global Gestational Diabetes Market by Region, 2020 – 2027, (USD Million)

    Table 4 Global Gestational Diabetes Market by Types, 2020 – 2027, (USD Million)

    Table 5 Global Gestational Diabetes Market by Administration, 2020 – 2027, (USD Million)

    Table 6 Global Gestational Diabetes Market by Treatment, 2020 – 2027, (USD Million)

    Table 7 Global Gestational Diabetes Market by End Users, 2020 – 2027, (USD Million)

    Table 8 North America Gestational Diabetes Market by Types, 2020 – 2027, (USD Million)

    Table 9 North America Gestational Diabetes Market by Administration, 2020 – 2027, (USD Million)

    Table 10 North America Gestational Diabetes Market by Treatment, 2020 – 2027, (USD Million)

    Table 11 North America Gestational Diabetes Market by End Users, 2020 – 2027, (USD Million)

    Table 12 US Market by Types, 2020 – 2027, (USD Million)

    Table 13 US Gestational Diabetes Market by Administration, 2020 – 2027, (USD Million)

    Table 14 US Gestational Diabetes Market by Treatment, 2020 – 2027, (USD Million)

    Table 15 US Gestational Diabetes Market by End Users, 2020 – 2027, (USD Million)

    Table 16 Canada Market by Types, 2020 – 2027, (USD Million)

    Table 17 Canada Gestational Diabetes Market by Administration, 2020 – 2027, (USD Million)

    Table 18 Canada Gestational Diabetes Market by Treatment, 2020 – 2027, (USD Million)

    Table 19 Canada Gestational Diabetes Market by End Users, 2020 – 2027, (USD Million)

    Table 20 South America Market by Types, 2020 – 2027, (USD Million)

    Table 21 South America Gestational Diabetes Market by Administration, 2020 – 2027, (USD Million)

    Table 22 South America Gestational Diabetes Market by Treatment, 2020 – 2027, (USD Million)

    Table 23 South America Gestational Diabetes Market by End Users, 2020 – 2027, (USD Million)

    Table 24 Europe Market by Types, 2020 – 2027, (USD Million)

    Table 25 Europe Gestational Diabetes Market by Administration, 2020 – 2027, (USD Million)

    Table 26 Europe Gestational Diabetes Market by Treatment, 2020 – 2027, (USD Million)

    Table 27 Europe Gestational Diabetes Market by End Users, 2020 – 2027, (USD Million)

    Table 28 Western Europe Market by Types, 2020 – 2027, (USD Million)

    Table 29 Western Europe Gestational Diabetes Market by Administration, 2020 – 2027, (USD Million)

    Table 30 Western Europe Gestational Diabetes Market by Treatment, 2020 – 2027, (USD Million)

    Table 31 Western Europe Gestational Diabetes Market by End Users, 2020 – 2027, (USD Million)

    Table 32 Eastern Europe Market by Types, 2020 – 2027, (USD Million)

    Table 33 Eastern Europe Gestational Diabetes Market by Administration, 2020 – 2027, (USD Million)

    Table 34 Eastern Europe Gestational Diabetes Market by Treatment, 2020 – 2027, (USD Million)

    Table 35 Eastern Europe Gestational Diabetes Market by End Users, 2020 – 2027, (USD Million)

    Table 36 Asia Pacific Market by Types, 2020 – 2027, (USD Million)

    Table 37 Asia Pacific Gestational Diabetes Market by Administration, 2020 – 2027, (USD Million)

    Table 38 Asia Pacific Gestational Diabetes Market by Treatment, 2020 – 2027, (USD Million)

    Table 39 Asia Pacific Gestational Diabetes Market by End Users, 2020 – 2027, (USD Million)

    Table 40 Middle East & Africa Market by Types, 2020 – 2027, (USD Million)

    Table 41 Middle East & Africa Gestational Diabetes Market by Administration, 2020 – 2027, (USD Million)

    Table 42 Middle East & Africa Gestational Diabetes Market by Treatment, 2020 – 2027, (USD Million)

    Table 43 Middle East & Africa Gestational Diabetes Market by End Users, 2020 – 2027, (USD Million)

    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation for Global Gestational Diabetes Market

    Figure 3 Segmentation Market Dynamics for Global Gestational Diabetes Market

    Figure 4 Global Gestational Diabetes market Share, by Type 2020

    Figure 5 Global Gestational Diabetes market Share, by Administration 2020

    Figure 6 Global Gestational Diabetes market Share, by Treatment 2020

    Figure 7 Global Gestational Diabetes Market Share, by End Users, 2020

    Figure 8 Global Gestational Diabetes Market Share, by Region, 2020

    Figure 9 North America Gestational Diabetes Market Share, by Country, 2020

    Figure 10 Europe Gestational Diabetes Market Share, by Country, 2020

    Figure 11 Asia Pacific Gestational Diabetes Market Share, by Country, 2020

    Figure 12 Middle East & Africa Gestational Diabetes Market Share, by Country, 2020

    Figure 13 Global Gestational Diabetes Market: Company Share Analysis, 2020 (%)

    Figure 14 Novartis AG: Key Financials

    Figure 15 Novartis AG: Segmental Revenue

    Figure 16 Novartis AG: Geographical Revenue

    Figure 17 Antares Pharma: Key Financials

    Figure 18 Antares Pharma: Segmental Revenue

    Figure 19 Antares Pharma: Geographical Revenue

    Figure 20 Eli Lilly: Key Financials

    Figure 21 Eli Lilly: Segmental Revenue

    Figure 22 Eli Lilly: Geographical Revenue

    Figure 23 Biocon: Key Financials

    Figure 24 Biocon: Segmental Revenue

    Figure 25 Biocon: Geographical Revenue

    Figure 26 Sanof: Key Financials

    Figure 27 Sanofi: Segmental Revenue

    Figure 28 Sanofi: Geographical Revenue

    Figure 29 Abbott: Key Financials

    Figure 30 Abbott: Segmental Revenue

    Figure 31 Abbott: Geographical Revenue

    Figure 32 AstraZeneca: Key Financials

    Figure 33 AstraZeneca: Segmental Revenue

    Figure 34 AstraZeneca: Geographical Revenue